| NCT ID | NCT06895291 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Condition | Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-10-26 |
| Primary Completion | 2028-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-10-26 with a primary completion date of 2028-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.
Eligibility Criteria
Inclusion Criteria: * Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above. * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged ≥ 18 years. * Life expectancy greater than 3 months. Exclusion Criteria: * Patients with MRI-unsafe prostheses and devices. * Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.
Contact & Investigator
Alice Rossi
PRINCIPAL INVESTIGATOR
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
Frequently Asked Questions
Who can join the NCT06895291 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06895291 currently recruiting?
Yes, NCT06895291 is actively recruiting participants. Contact the research team at cc.ubsc@irst.emr.it for enrollment information.
Where is the NCT06895291 trial being conducted?
This trial is being conducted at Bologna, Italy, Meldola, Italy, Milan, Italy.
Who is sponsoring the NCT06895291 clinical trial?
NCT06895291 is sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. The principal investigator is Alice Rossi at IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.. The trial plans to enroll 1,000 participants.